Experienced in Frostbite

Agnieszka Zebrowska

NZOZ ALL MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie
Lodz, LD, PL 
Experienced in Frostbite
NZOZ ALL MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie
Lodz, LD, PL 
OverviewLocationsClinical Research

Overview

Agnieszka Zebrowska practices in Lodz, Poland. Ms. Zebrowska is rated as an Experienced expert by MediFind in the treatment of Frostbite. Her top areas of expertise are Dermatitis Herpetiformis, Bullous Pemphigoid, Pemphigus Foliaceus, and Pemphigus.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Frostbite.

Gender
Female

Locations

NZOZ ALL MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie
Lodz, LD, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis
Enrollment Status: Completed
Publish Date: December 05, 2022
Intervention Type: Drug
Study Drug: LY3361237
Study Phase: Phase 1

34 Total Publications

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52).
A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52).
Journal: Journal of the American Academy of Dermatology
Published: April 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zebrowska's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile